Steven Ruhl is CURE’s VP of Manufacturing, overseeing all process development and manufacturing operations. He is a seasoned leader for drug substance and drug products process development, production facility design, process equipment, construction and CGMP management. He has a proven track record with building and developing high performing teams to deliver commercial supply and process solutions that meet regulatory requirements. Mr. Ruhl brings more than 35 years of experience leading technical teams. Most recently he served 11 years at Amgen Thousand Oaks in multiple process development roles. As Process Development Director of Generation Technologies he led the introduction and commissioning of a next generation isolated drug product robotic filler. Prior to that he served 4 years at Amgen Technologies Ireland as Process Development Site and Tech Transfer Program Lead for multiple Amgen Commercial products where he co-led a $350M capital expansion of an Amgen acquired Pfizer site to expand site capabilities to manufacture, package and cold store finished drug product. Steven entered Amgen in 2007 as Commercial Drug Product Executive Director responsible for global support and lifecycle management of Amgen’s commercial products. Previously, Steven held management positions at CancerVax, Certified Facilities, IDEC Pharmaceuticals, Xoma and Celtrix Pharmaceuticals. He served IDEC during the time of two firsts for monoclonal antibody therapies with development and launch of Rituxan® and co-led the CMC development for Zevalin® radioimmune conjugate. He trained as microbiologist and chemist at Brigham Young University.